| Date | Title | Description |
| 16.09.2024 | Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm | Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
Mon, Sep 16, 2024 15:30 CET Report this content
Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm. The last day of... |
| 06.09.2024 | Calliditas Therapeutics: A New Chapter Begins Amidst Corporate Changes | In the world of pharmaceuticals, change is the only constant. Calliditas Therapeutics AB, a biopharmaceutical company based in Stockholm, is poised to undergo significant transformations following a recent announcement from Asahi Kasei Corp... |
| 03.09.2024 | Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei | Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
Tue, Sep 03, 2024 12:15 CET Report this content
Stockholm, Sweden, September 3, 2024 – Following the announcement by Asahi Kasei Corporation (“Asa... |
| 14.08.2024 | Calliditas and Asahi Kasei: A Strategic Dance in the Biopharma Arena | In the fast-paced world of biopharmaceuticals, every move counts. Calliditas Therapeutics AB, a Swedish biopharma company, recently unveiled its interim report for the first half of 2024. The numbers tell a story of growth, challenges, and ... |
| 13.08.2024 | Calliditas Interim Report January to June 2024 | Calliditas Interim Report January to June 2024
Tue, Aug 13, 2024 07:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX):
April to June 2024 (compared to April to June 2023) Net sales amounted to SEK... |
| 05.08.2024 | Invitation to the presentation of Calliditas´s interim report January – June 2024 | Invitation to the presentation of Calliditas´s interim report January – June 2024
Mon, Aug 05, 2024 07:00 CET Report this content
Calliditas's interim report for the second quarter, April – June 2024 will be published in Swedish and English... |
| 31.07.2024 | Calliditas Therapeutics: Navigating Shareholder Waters Amidst Corporate Changes | In the world of finance, numbers tell stories. They pulse with the rhythm of market dynamics, reflecting the health of companies and the sentiments of investors. Calliditas Therapeutics AB, a biopharmaceutical company based in Stockholm, re... |
| 31.07.2024 | Number of shares and votes in Calliditas Therapeutics | Number of shares and votes in Calliditas Therapeutics
Wed, Jul 31, 2024 14:00 CET Report this content
During July, the number of shares and votes in Calliditas Therapeutics AB (publ) has changed due to the exercise of warrants under the com... |
| 27.07.2024 | Calliditas Therapeutics: A Beacon of Hope in Rare Disease Treatment | In the ever-evolving landscape of biopharmaceuticals, Calliditas Therapeutics is making waves. The company recently announced significant advancements in two of its key treatments, setanaxib and Kinpeygo, which target rare diseases with sub... |
| 26.07.2024 | Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy | Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
Fri, Jul 26, 2024 17:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: C... |
| 26.07.2024 | Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis | Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
Fri, Jul 26, 2024 08:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced t... |
| 04.07.2024 | Launch of Phase 3 clinical trial with Nefecon in Japan | Launch of Phase 3 clinical trial with Nefecon in Japan
Thu, Jul 04, 2024 08:30 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announces that its partner Viatris Pharmaceutical... |
| 18.06.2024 | Calliditas provides setanaxib patent update | Calliditas provides setanaxib patent update
Tue, Jun 18, 2024 12:15 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the United States Patent and Trademark Office... |
| 17.06.2024 | Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) | Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
Mon, Jun 17, 2024 17:30 CET Report this content
The following resolutions were passed at Calliditas Therapeutics AB (publ) (“Calliditas”) annual general meeting h... |
| 30.05.2024 | Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy | Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy
Thu, May 30, 2024 20:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockho... |
| 28.05.2024 | Asahi Kasei announces a recommended public cash offer to the shareholders and ADS holders of Calliditas | Asahi Kasei announces a recommended public cash offer to the shareholders and ADS holders of Calliditas
Tue, May 28, 2024 08:15 CET Report this content
THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY OR THE SOLICITATION OF AN OFFER T... |
| 28.05.2024 | Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation | Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
Tue, May 28, 2024 08:30 CET Report this content
The Board of Directors of Calliditas Therapeutics AB (publ) ... |
| 28.05.2024 | Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress | Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress
Tue, May 28, 2024 14:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced the p... |
| 23.05.2024 | Calliditas Q1 report, January – March 2024 | Calliditas Q1 report, January – March 2024
Thu, May 23, 2024 07:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX):
Target market expansion following full approval in the US
JANUARY – MARCH 2024 (COMPARED TO JAN... |
| 16.05.2024 | Invitation to the presentation of Calliditas´s interim report January – March 2024 | Invitation to the presentation of Calliditas´s interim report January – March 2024
Thu, May 16, 2024 08:30 CET Report this content
Calliditas´s interim report for the first quarter, January – March 2024 will be published in Swedish and Engl... |
| 16.05.2024 | In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO’s Mode of Action | In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO’s Mode of Action
Thu, May 16, 2024 16:30 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today... |
| 15.05.2024 | Calliditas Therapeutics to Present Data at ERA 2024 May 23 – 26 in Stockholm | Calliditas Therapeutics to Present Data at ERA 2024 May 23 – 26 in Stockholm
Wed, May 15, 2024 14:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced upcoming data pr... |
| 14.05.2024 | Calliditas’ Partner Everest Medicines Starts Commercial Launch of Nefecon in China | Calliditas’ Partner Everest Medicines Starts Commercial Launch of Nefecon in China
Tue, May 14, 2024 13:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announces that its pa... |
| 06.05.2024 | Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib | Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
Mon, May 06, 2024 08:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CAL... |
| 24.04.2024 | Calliditas Therapeutics’ 2023 Annual Report Published | Calliditas Therapeutics’ 2023 Annual Report Published
Wed, Apr 24, 2024 19:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announces that the Annual Report for 2023 now is a... |
| 24.04.2024 | Calliditas Announces Positive NefIgArd Open Label Extension Results | Calliditas Announces Positive NefIgArd Open Label Extension Results
Wed, Apr 24, 2024 08:30 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the global open-label... |
| 18.04.2024 | Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024 | Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Thu, Apr 18, 2024 13:00 CET Report this content
Calliditas Therapeu... |
| 09.04.2024 | Calliditas Therapeutics to Attend Conferences in April | Calliditas Therapeutics to Attend Conferences in April
Tue, Apr 09, 2024 13:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), a commercial biopharma company focused on rare disease... |
| 08.04.2024 | Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 – 16 in Buenos Aires | Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 – 16 in Buenos Aires
Mon, Apr 08, 2024 14:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calli... |
| 08.04.2024 | Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment | Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
Mon, Apr 08, 2024 09:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Callidi... |
| 20.03.2024 | Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients | SHANGHAI, March 20, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative... |
| 06.03.2024 | Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO® | Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
Wed, Mar 06, 2024 08:15 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that... |
| 01.03.2024 | Calliditas Therapeutics to Attend Investor Conferences in March | Calliditas Therapeutics to Attend Investor Conferences in March
Fri, Mar 01, 2024 13:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), a commercial biopharma company focused on rar... |
| 21.02.2024 | Calliditas Year-end report, January – December 2023 | Calliditas Year-end report, January – December 2023
Wed, Feb 21, 2024 07:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX)
2023: Full approval for TARPEYO in the US; a year of successes
OCTOBER – DECEMBER 2023(... |
| 14.02.2024 | Invitation to the presentation of Calliditas´ Year-end report January – December 2023 | Invitation to the presentation of Calliditas´ Year-end report January – December 2023
Wed, Feb 14, 2024 07:00 CET Report this content
Calliditas´ Year-end report for January – December 2023 will be published in Swedish and English on Wednes... |
| 13.02.2024 | Calliditas provides patent update | Calliditas provides patent update
Tue, Feb 13, 2024 17:15 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the United States Patent and Trademark Office (USPTO) i... |
| 08.01.2024 | Calliditas Therapeutics provides business update ahead of JP Morgan conference | Calliditas Therapeutics provides business update ahead of JP Morgan conference
Mon, Jan 08, 2024 08:15 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), a commercial biopharma company... |
| 07.01.2024 | Calliditas Therapeutics appoints Maria Törnsén as President North America | Calliditas Therapeutics appoints Maria Törnsén as President North America
Sun, Jan 07, 2024 17:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), a commercial biopharma company focu... |
| 07.01.2024 | Calliditas to present at JP Morgan Healthcare Conference | Calliditas to present at JP Morgan Healthcare Conference
Sun, Jan 07, 2024 15:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that management will present at and p... |
| 27.12.2023 | Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital | Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital
Wed, Dec 27, 2023 17:45 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) to... |
| 20.12.2023 | Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function | Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function
Wed, Dec 20, 2023 22:15 CET Report this content
Calliditas Therapeutics... |
| 11.12.2023 | Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO® | Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO®
Mon, Dec 11, 2023 15:15 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced... |
| 01.12.2023 | Calliditas announces additions to the management team | Calliditas announces additions to the management team
Fri, Dec 01, 2023 09:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the company has added a new member ... |
| 30.11.2023 | Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome | Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome
Thu, Nov 30, 2023 08:30 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced the initiation of... |
| 24.11.2023 | Calliditas’ partner Everest Medicines announces China NMPA’s approval of Nefecon® for the treatment of primary IgA nephropathy | Calliditas’ partner Everest Medicines announces China NMPA’s approval of Nefecon® for the treatment of primary IgA nephropathy
Fri, Nov 24, 2023 08:45 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX... |
| 07.11.2023 | Calliditas to present at upcoming investor conferences | Calliditas to present at upcoming investor conferences
Tue, Nov 07, 2023 16:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that management will present at and par... |
| 06.11.2023 | Calliditas Presents Additional Data Analyses from the NefIgArd Phase 3 trial at the American Society of Nephrology (ASN) Kidney Week 2023 | Calliditas Presents Additional Data Analyses from the NefIgArd Phase 3 trial at the American Society of Nephrology (ASN) Kidney Week 2023
Mon, Nov 06, 2023 21:30 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stock... |
| 27.10.2023 | New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy | New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy
Fri, Oct 27, 2023 09:15 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq St... |
| 19.10.2023 | Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 | Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
Thu, Oct 19, 2023 08:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”... |
| 03.10.2023 | Calliditas announces filing with UK MHRA for Kinpeygo in IgA nephropathy | Calliditas announces filing with UK MHRA for Kinpeygo in IgA nephropathy
Tue, Oct 03, 2023 09:20 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that its partner STAD... |
| 29.09.2023 | Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023 | Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023
Fri, Sep 29, 2023 14:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: ... |
| 28.09.2023 | STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU | STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU
Thu, Sep 28, 2023 12:01 CET Report this content
Request submitted by STADA to EMA to convert conditional marketing authorization to standard ma... |
| 19.09.2023 | Calliditas Therapeutics to Present Nefecon Data at the 17[th] International Symposium on IgA Nephropathy (IIgANN) September 25-27 in Tokyo | Calliditas Therapeutics to Present Nefecon Data at the 17[th] International Symposium on IgA Nephropathy (IIgANN) September 25-27 in Tokyo
Tue, Sep 19, 2023 16:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stoc... |
| 18.08.2023 | FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy | FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy
Fri, Aug 18, 2023 10:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced ... |
| 17.08.2023 | Interim Report Q2, 2023 | Interim Report Q2, 2023
Thu, Aug 17, 2023 07:00 CET Report this content
Filing for full approval of TARPEYO
FINANCIAL SUMMARY FOR THE GROUP
Key Figures
April 1 - June 30, 2023 Net sales amounted to SEK 269.4 million, of which TARPEYO® net s... |
| 15.08.2023 | Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet | Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet
Tue, Aug 15, 2023 08:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today a... |
| 21.06.2023 | Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO[®] | Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO[®]
Wed, Jun 21, 2023 09:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockhol... |
| 30.05.2023 | Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) | Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
Tue, May 30, 2023 16:00 CET Report this content
The following resolutions were passed at Calliditas Therapeutics AB (publ) (“Calliditas”) annual general meeting h... |
| 05.05.2023 | Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023 | Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023
Fri, May 05, 2023 14:30 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) an... |
| 28.04.2023 | Notice of annual general meeting of Calliditas Therapeutics AB (publ) | Notice of annual general meeting of Calliditas Therapeutics AB (publ)
Fri, Apr 28, 2023 08:30 CET Report this content
The shareholders of Calliditas Therapeutics AB (publ) (“Calliditas Therapeutics”), Reg. No. 556659-9766, with registered o... |
| 26.04.2023 | Calliditas Therapeutics’ 2022 Annual Report Published | Calliditas Therapeutics’ 2022 Annual Report Published
Wed, Apr 26, 2023 21:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2022 now is available at the... |
| 31.03.2023 | Calliditas to participate in upcoming investor conferences | Calliditas to participate in upcoming investor conferences
Fri, Mar 31, 2023 17:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced its management’s participation in t... |
| 12.03.2023 | Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon[®] in IgA Nephropathy | Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon[®] in IgA Nephropathy
Sun, Mar 12, 2023 18:30 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“C... |
| 23.02.2023 | Year-End Report, 2022 | Year-End Report, 2022
Thu, Feb 23, 2023 07:00 CET Report this content
2022: Successful transformation into a commercial stage company
“2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approved drug for I... |
| 02.02.2023 | Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy | Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy
Thu, Feb 02, 2023 09:15 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today ann... |
| 30.12.2022 | China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy | STOCKHOLM, Dec. 30, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Ad... |
| 30.12.2022 | Number of shares and votes in Calliditas Therapeutics | STOCKHOLM, Dec. 30, 2022 /PRNewswire/ -- During December, Calliditas Therapeutics AB (publ) has issued 415,000 common shares connected to the company's long term incentive program 2019/2022. Thus, as of December 30, 2022, the number of shar... |
| 30.12.2022 | China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy | China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy
Fri, Dec 30, 2022 08:30 CET Report this content
Calliditas Therapeutics AB (publ) (“Calliditas”) partner Everest Medicines (HKEX 1952.HK) tod... |
| 20.12.2022 | Calliditas CEO acquires shares through the exercise of Calliditas’ warrant program 2019/2022 | Calliditas CEO acquires shares through the exercise of Calliditas’ warrant program 2019/2022
Tue, Dec 20, 2022 21:15 CET Report this content
Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (”Calliditas”) announced ... |
| 13.12.2022 | Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan | Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan
Tue, Dec 13, 2022 08:00 CET Report this content
Calliditas announces that it has entered into an a... |
| 09.12.2022 | Calliditas to host fireside chat with its China commercial partner, Everest Medicines | STOCKHOLM, Dec. 9, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a fireside chat with its commercial partner Everest Medicines (HKEX 1952.HK, "Everest") on Wednes... |
| 09.12.2022 | Calliditas to host fireside chat with its China commercial partner, Everest Medicines | Calliditas to host fireside chat with its China commercial partner, Everest Medicines
Fri, Dec 09, 2022 08:00 CET Report this content
Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that it will host a fireside chat with it... |
| 15.11.2022 | Calliditas’ partner Everest Medicine’s New Drug Application for Nefecon is accepted by the China NMPA | Calliditas’ partner Everest Medicine’s New Drug Application for Nefecon is accepted by the China NMPA
Tue, Nov 15, 2022 08:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today an... |
| 14.11.2022 | Interim Report Q3, 2022 | Interim Report Q3, 2022
Mon, Nov 14, 2022 07:00 CET Report this content
Conditional Marketing Authorization in EU Granted for Kinpeygo®
“On July 15th the European Commission issued the conditional marketing authorization for Kinpeygo, which... |
| 07.11.2022 | Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape | Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape
Mon, Nov 07, 2022 09:00 CET Report this content
Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that it will host a Key Op... |
| 20.09.2022 | Calliditas’ partner STADA launches the first medicine authorized in the EU for treating primary IgA nephropathy | Calliditas’ partner STADA launches the first medicine authorized in the EU for treating primary IgA nephropathy
Tue, Sep 20, 2022 14:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”... |
| 18.08.2022 | Interim Report Q2, 2022 | Interim Report Q2, 2022
Thu, Aug 18, 2022 07:00 CET Report this content
European approval for Kinpeygo®
“On May 19th, the European Medicines Agency (EMA) announced that it had adopted a positive opinion regarding the application for conditi... |
| 18.08.2022 | Calliditas Therapeutics: Interim Report Q2, 2022 | STOCKHOLM, Aug. 18, 2022 /PRNewswire/ --
European approval for Kinpeygo®
"On May 19th, the European Medicines Agency (EMA) announced that it had adopted a positive opinion regarding the application for conditional approval of Kinpeygo®... |
| 15.07.2022 | European Commission approves Kinpeygo® for adults with primary IgA nephropathy | European Commission approves Kinpeygo® for adults with primary IgA nephropathy
Fri, Jul 15, 2022 17:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the Europe... |
| 11.07.2022 | Calliditas announces additions to the management team | Calliditas announces additions to the management team
Mon, Jul 11, 2022 12:30 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the company has added two members t... |
| 28.06.2022 | Calliditas Therapeutics establishes a U.S. At-the-Market Program | Calliditas Therapeutics establishes a U.S. At-the-Market Program
Tue, Jun 28, 2022 23:15 CET Report this content
Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas” or “the Company”) today announced that ... |
| 20.06.2022 | Issuance and repurchase of C-shares to establish an at-the-market program | Issuance and repurchase of C-shares to establish an at-the-market program
Mon, Jun 20, 2022 21:15 CET Report this content
The Board of Directors of Calliditas Therapeutics AB (publ) today resolved to carry out a new issue of 5,908,018 C-sha... |
| 19.05.2022 | Calliditas receives positive CHMP opinion in IgA nephropathy | Calliditas receives positive CHMP opinion in IgA nephropathy
Thu, May 19, 2022 14:30 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the Committee for Medicinal ... |
| 18.05.2022 | Interim Report Q1, 2022 | Interim Report Q1, 2022
Wed, May 18, 2022 07:00 CET Report this content
Start of TARPEYO™ Commercial Launch in the US
“During the first quarter Calliditas launched its first commercial product, TARPEYO, in the US, supported by 40 experience... |
| 17.05.2022 | First patient randomized in Phase 2 trial in head and neck cancer | First patient randomized in Phase 2 trial in head and neck cancer
Tue, May 17, 2022 11:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the first patient has b... |
| 10.05.2022 | Calliditas Therapeutics to participate in upcoming investor conferences | Calliditas Therapeutics to participate in upcoming investor conferences
Tue, May 10, 2022 08:30 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that its management te... |
| 27.04.2022 | Calliditas Therapeutics’ 2021 Annual Report Published | Calliditas Therapeutics’ 2021 Annual Report Published
Wed, Apr 27, 2022 18:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2021 now is available at the... |
| 24.03.2022 | Calliditas CEO acquires shares through the exercise of Calliditas’ warrant program 2018/2022 | Calliditas CEO acquires shares through the exercise of Calliditas’ warrant program 2018/2022
Thu, Mar 24, 2022 12:00 CET Report this content
Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") ... |
| 22.03.2022 | Calliditas provides a regulatory update on EMA process for Nefecon | Calliditas provides a regulatory update on EMA process for Nefecon
Tue, Mar 22, 2022 08:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the opinion of the Com... |
| 18.03.2022 | Updated regulatory plans for NEFECON in China | Updated regulatory plans for NEFECON in China
Fri, Mar 18, 2022 08:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that partner Everest Medicines (HKEX 1952.HK) pl... |
| 14.03.2022 | Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea | SHANGHAI, March 14, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets,... |
| 14.03.2022 | Expansion of Everest Medicine’s licence agreement to include South Korea | Expansion of Everest Medicine’s licence agreement to include South Korea
Mon, Mar 14, 2022 07:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the company has ... |
| 24.02.2022 | Year-End Report, 2021 | Year-End Report, 2021
Thu, Feb 24, 2022 07:00 CET Report this content
Calliditas became the first Company to receive accelerated approval in IgA Nephropathy.
“The accelerated approval of TARPEYO was for the indication of reduction of protei... |
| 15.02.2022 | First patient randomized in pivotal TRANSFORM study with setanaxib | First patient randomized in pivotal TRANSFORM study with setanaxib
Tue, Feb 15, 2022 10:30 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the first patient has ... |
| 28.01.2022 | Calliditas Therapeutics Announces Commercial Availability and Initial Sales of TARPEYO™ | Calliditas Therapeutics Announces Commercial Availability and Initial Sales of TARPEYO™ Fri, Jan 28, 2022 08:00 CET
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced the commercial availabilit... |
| 16.12.2021 | Everest Medicines announces FDA grants our Partner Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy | TARPEYO (budesonide) delayed release capsules is the first and only treatment indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-crea... |
| 18.11.2021 | Calliditas Therapeutics: Interim Report Q3, 2021 | STOCKHOLM, Nov. 18, 2021 /PRNewswire/ -- "Following on from the positive top line read out of Part A our Phase 3 study, we initiated a structured process to select our commercial partner for Nefecon in Europe. In this case, the result ... |
| 03.11.2021 | Calliditas announces poster presentations at ASN Digital Kidney Week 2021 | Calliditas announces poster presentations at ASN Digital Kidney Week 2021 Wed, Nov 03, 2021 08:00 CET
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced upcoming presentations concerning Nefeco... |
| 07.10.2021 | Calliditas announces acquisition of remaining Genkyotex minority shares | Calliditas announces acquisition of remaining Genkyotex minority shares Thu, Oct 07, 2021 08:00 CET
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the company now controls 100% of the ... |
| 16.09.2021 | Updated regulatory timeline for review of MAA in Europe. | Updated regulatory timeline for review of MAA in Europe. Thu, Sep 16, 2021 14:30 CET
Calliditas Therapeutics AB (publ) (”Calliditas” or the ”Company”) (Nasdaq Stockholm – CALTX; Nasdaq – CALT), a biopharma company focused on identifying, de... |